Sight Sciences (SGHT)
Market Price (9/2/2026): $8.07 | Market Cap: $439.9 MilSector: Health Care | Industry: Life Sciences Tools & Services
Sight Sciences (SGHT)
Market Price (9/2/2026): $8.07Market Cap: $439.9 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management. | Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -45% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33% Stock price has recently run up significantly12M Rtn12 month market price return is 102% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.9% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -28% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 109% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% Key risksSGHT key risks include [1] adverse Medicare coverage decisions severely limiting reimbursement for its core OMNI and TearCare systems, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management. |
| Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -45% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 102% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.9% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -28% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 109% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Key risksSGHT key risks include [1] adverse Medicare coverage decisions severely limiting reimbursement for its core OMNI and TearCare systems, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/1/2026
Sight Sciences (SGHT) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. FDA Clearance of the OMNI Ultra Surgical System.
Sight Sciences received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI Ultra Surgical System on August 4, 2026. This new system, designed for minimally invasive glaucoma surgery (MIGS), is notable as the first FDA-cleared MIGS device for circumferential canaloplasty in a single pass, which is expected to expand the company's leadership in interventional glaucoma.
2. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Guidance.
On August 5, 2026, Sight Sciences reported strong financial results for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst expectations. The company posted an earnings per share (EPS) loss of $0.08, beating the consensus estimate of a $0.18 loss, and reported revenue of $23.39 million, surpassing analyst expectations of $21.72 million. This represented a 20% increase in revenue compared to fiscal Q2 2025. Furthermore, Interventional Dry Eye (IDE) revenue saw substantial growth, increasing by 704% year-over-year to $2.7 million. Following these results, Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million, up from the prior guidance of $83 million to $89 million, and reduced its full-year 2026 adjusted operating expense guidance to $92 million to $94 million from $93 million to $96 million, signaling improving operational efficiency.
Show more
Sight Sciences (SGHT) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. FDA Clearance of the OMNI Ultra Surgical System.
Sight Sciences received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI Ultra Surgical System on August 4, 2026. This new system, designed for minimally invasive glaucoma surgery (MIGS), is notable as the first FDA-cleared MIGS device for circumferential canaloplasty in a single pass, which is expected to expand the company's leadership in interventional glaucoma.
2. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Guidance.
On August 5, 2026, Sight Sciences reported strong financial results for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst expectations. The company posted an earnings per share (EPS) loss of $0.08, beating the consensus estimate of a $0.18 loss, and reported revenue of $23.39 million, surpassing analyst expectations of $21.72 million. This represented a 20% increase in revenue compared to fiscal Q2 2025. Furthermore, Interventional Dry Eye (IDE) revenue saw substantial growth, increasing by 704% year-over-year to $2.7 million. Following these results, Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million, up from the prior guidance of $83 million to $89 million, and reduced its full-year 2026 adjusted operating expense guidance to $92 million to $94 million from $93 million to $96 million, signaling improving operational efficiency.
Show more
Updated on 9/1/2026
Sight Sciences (SGHT) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. FDA Clearance of the OMNI Ultra Surgical System.
Sight Sciences received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI Ultra Surgical System on August 4, 2026. This new system, designed for minimally invasive glaucoma surgery (MIGS), is notable as the first FDA-cleared MIGS device for circumferential canaloplasty in a single pass, which is expected to expand the company's leadership in interventional glaucoma.
2. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Guidance.
On August 5, 2026, Sight Sciences reported strong financial results for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst expectations. The company posted an earnings per share (EPS) loss of $0.08, beating the consensus estimate of a $0.18 loss, and reported revenue of $23.39 million, surpassing analyst expectations of $21.72 million. This represented a 20% increase in revenue compared to fiscal Q2 2025. Furthermore, Interventional Dry Eye (IDE) revenue saw substantial growth, increasing by 704% year-over-year to $2.7 million. Following these results, Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million, up from the prior guidance of $83 million to $89 million, and reduced its full-year 2026 adjusted operating expense guidance to $92 million to $94 million from $93 million to $96 million, signaling improving operational efficiency.
3. Expanded Reimbursement and Product Indications.
Sight Sciences benefited from expanded market access and product indications during the period. On August 5, 2026, Aetna, Inc. updated its Glaucoma Surgery Policy to recognize the OMNI Surgical System as "medically necessary" for the treatment of mild-to-moderate primary open-angle glaucoma, broadening commercial coverage. Additionally, on August 19, 2026, the FDA expanded the TearCare System's Indications for Use, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.
4. Positive Analyst Sentiment and Increased Price Targets.
Following the strong Q2 2026 results and significant product and reimbursement news, several analysts upgraded their ratings or increased their price targets for SGHT stock. For instance, on August 6, 2026, UBS Group increased its price target from $7.00 to $8.00 while maintaining a "buy" rating. The average analyst price target also rose to $9.00, reflecting a consensus "Buy" rating and a positive outlook on the stock's future performance.
Show less
Sight Sciences (SGHT) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. FDA Clearance of the OMNI Ultra Surgical System.
Sight Sciences received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI Ultra Surgical System on August 4, 2026. This new system, designed for minimally invasive glaucoma surgery (MIGS), is notable as the first FDA-cleared MIGS device for circumferential canaloplasty in a single pass, which is expected to expand the company's leadership in interventional glaucoma.
2. Robust Fiscal Q2 2026 Financial Performance and Raised Full-Year Guidance.
On August 5, 2026, Sight Sciences reported strong financial results for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analyst expectations. The company posted an earnings per share (EPS) loss of $0.08, beating the consensus estimate of a $0.18 loss, and reported revenue of $23.39 million, surpassing analyst expectations of $21.72 million. This represented a 20% increase in revenue compared to fiscal Q2 2025. Furthermore, Interventional Dry Eye (IDE) revenue saw substantial growth, increasing by 704% year-over-year to $2.7 million. Following these results, Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million, up from the prior guidance of $83 million to $89 million, and reduced its full-year 2026 adjusted operating expense guidance to $92 million to $94 million from $93 million to $96 million, signaling improving operational efficiency.
3. Expanded Reimbursement and Product Indications.
Sight Sciences benefited from expanded market access and product indications during the period. On August 5, 2026, Aetna, Inc. updated its Glaucoma Surgery Policy to recognize the OMNI Surgical System as "medically necessary" for the treatment of mild-to-moderate primary open-angle glaucoma, broadening commercial coverage. Additionally, on August 19, 2026, the FDA expanded the TearCare System's Indications for Use, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.
4. Positive Analyst Sentiment and Increased Price Targets.
Following the strong Q2 2026 results and significant product and reimbursement news, several analysts upgraded their ratings or increased their price targets for SGHT stock. For instance, on August 6, 2026, UBS Group increased its price target from $7.00 to $8.00 while maintaining a "buy" rating. The average analyst price target also rose to $9.00, reflecting a consensus "Buy" rating and a positive outlook on the stock's future performance.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 68.5% change in SGHT stock from 5/31/2026 to 9/1/2026 was primarily driven by a 62.5% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.86 | 8.19 | 68.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 80 | 83 | 4.8% |
| P/S Multiple | 3.3 | 5.4 | 62.5% |
| Shares Outstanding (Mil) | 54 | 55 | -1.0% |
| Cumulative Contribution | 68.5% |
Market Drivers
5/31/2026 to 9/1/2026| Return | Correlation | |
|---|---|---|
| SGHT | 68.5% | |
| Market (SPY) | 0.7% | 11.9% |
| Sector (XLV) | 14.9% | 20.2% |
Fundamental Drivers
The 58.7% change in SGHT stock from 2/28/2026 to 9/1/2026 was primarily driven by a 50.7% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.16 | 8.19 | 58.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 76 | 83 | 9.6% |
| P/S Multiple | 3.6 | 5.4 | 50.7% |
| Shares Outstanding (Mil) | 52 | 55 | -3.9% |
| Cumulative Contribution | 58.7% |
Market Drivers
2/28/2026 to 9/1/2026| Return | Correlation | |
|---|---|---|
| SGHT | 58.7% | |
| Market (SPY) | 11.4% | 23.3% |
| Sector (XLV) | 7.6% | 26.5% |
Fundamental Drivers
The 101.7% change in SGHT stock from 8/31/2025 to 9/1/2026 was primarily driven by a 94.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.06 | 8.19 | 101.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 76 | 83 | 9.3% |
| P/S Multiple | 2.8 | 5.4 | 94.2% |
| Shares Outstanding (Mil) | 52 | 55 | -4.9% |
| Cumulative Contribution | 101.7% |
Market Drivers
8/31/2025 to 9/1/2026| Return | Correlation | |
|---|---|---|
| SGHT | 101.7% | |
| Market (SPY) | 19.1% | 27.6% |
| Sector (XLV) | 26.5% | 25.4% |
Fundamental Drivers
The 24.8% change in SGHT stock from 8/31/2023 to 9/1/2026 was primarily driven by a 37.1% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.56 | 8.19 | 24.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 82 | 83 | 2.3% |
| P/S Multiple | 3.9 | 5.4 | 37.1% |
| Shares Outstanding (Mil) | 49 | 55 | -11.0% |
| Cumulative Contribution | 24.8% |
Market Drivers
8/31/2023 to 9/1/2026| Return | Correlation | |
|---|---|---|
| SGHT | 24.8% | |
| Market (SPY) | 75.1% | 26.9% |
| Sector (XLV) | 34.9% | 21.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SGHT Return | -48% | -31% | -58% | -29% | 118% | 7% | -75% |
| Peers Return | 19% | -20% | -8% | -19% | 37% | 5% | 2% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| SGHT Win Rate | 33% | 58% | 33% | 42% | 50% | 50% | |
| Peers Win Rate | 60% | 50% | 48% | 42% | 54% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SGHT Max Drawdown | - | -69% | -90% | -60% | -43% | -56% | |
| Peers Max Drawdown | -29% | -44% | -49% | -37% | -37% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, TECH, ATEC, CERS, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/1/2026 (YTD)
How Low Can It Go
| Event | SGHT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.8% | -18.8% |
| % Gain to Breakeven | 33.0% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -10.7% | -7.8% |
| % Gain to Breakeven | 12.0% | 8.5% |
| Time to Breakeven | 13 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -84.2% | -9.5% |
| % Gain to Breakeven | 533.3% | 10.5% |
| Time to Breakeven | 264 days | 24 days |
In The Past
Sight Sciences's stock fell -24.8% during the 2025 US Tariff Shock. Such a loss loss requires a 33.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SGHT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.8% | -18.8% |
| % Gain to Breakeven | 33.0% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -84.2% | -9.5% |
| % Gain to Breakeven | 533.3% | 10.5% |
| Time to Breakeven | 264 days | 24 days |
In The Past
Sight Sciences's stock fell -24.8% during the 2025 US Tariff Shock. Such a loss loss requires a 33.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sight Sciences (SGHT)
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device company that develops and commercializes both surgical and nonsurgical technologies for the treatment of various eye diseases. The company aims to provide innovative solutions that address significant needs within the eye care sector, empowering eye care professionals to better manage patient conditions.
The company's core product portfolio includes two primary systems. The OMNI Surgical System is a therapeutic device specifically designed for ophthalmic surgeons. It is used to reduce intraocular pressure in adult patients suffering from glaucoma, a leading cause of irreversible blindness. Alongside this, Sight Sciences offers the TearCare System, a wearable eyelid technology developed for ophthalmologists and optometrists to treat dry eye disease (DED), a widespread condition characterized by discomfort and potential vision impairment.
Sight Sciences primarily serves the United States market, distributing its products through a dedicated network of sales representatives and distributors. Its main customers include hospitals, medical centers, and a wide range of eyecare professionals, such as ophthalmic surgeons, ophthalmologists, and optometrists, who utilize these technologies to provide advanced care for their patients.
AI Analysis | Feedback
Here are 1-3 brief analogies for Sight Sciences (SGHT):
- Like a specialized Alcon (ALC), but focusing on innovative surgical and non-surgical devices for glaucoma and dry eye.
- Imagine a Dexcom (DXCM) or Insulet (PODD) for ophthalmology, developing specialized medical devices for chronic eye conditions like glaucoma and dry eye.
AI Analysis | Feedback
```html
- OMNI Surgical System: A therapeutic device used to reduce intraocular pressure in adult glaucoma patients.
- TearCare System: A wearable eyelid technology for the treatment of dry eye disease (DED).
AI Analysis | Feedback
Sight Sciences (SGHT) sells its products primarily to other companies and institutions within the healthcare sector. Its major customers are:
- Hospitals
- Medical Centers
- Eyecare Professionals (including ophthalmologists and optometrists, often operating in private practices or clinics)
AI Analysis | Feedback
null
AI Analysis | Feedback
Paul Badawi, Founder & Chief Executive Officer
Paul Badawi is the co-founder and Chief Executive Officer of Sight Sciences, Inc., serving in this role since 2011. He is a co-inventor of several of the company's key products, including the OMNI Surgical System and the TearCare System. Prior to co-founding Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm. In this role, he managed a portfolio of 12 medical device investments and $120 million invested, and served as a lead investor and board member for companies such as Ulthera (acquired by Merz), Xthetix (acquired by J&J), and NeoGuide (acquired by Intuitive Surgical). His prior experience also includes working as a Research Fellow at the National Institutes of Health.
James Rodberg, Chief Financial Officer and Treasurer
James Rodberg became the Chief Financial Officer of Sight Sciences, Inc. in November 2025, succeeding Alison Bauerlein. He joined Sight Sciences in early 2021 as Vice President of Finance and Corporate Controller and also served as interim CFO in 2023. With two decades of experience in public accounting and company finance leadership, his previous roles include Vice President of Finance, Planning and Analysis at nVent Electric, and Director of Finance at Abbott Laboratories. He also held several increasingly senior finance and accounting positions at St. Jude Medical prior to its acquisition by Abbott.
Alison Bauerlein, Chief Operating Officer
Alison Bauerlein was appointed Chief Operating Officer of Sight Sciences, Inc. in November 2025, a newly created position. She previously served as the company's Chief Financial Officer since joining in April 2023. Her experience includes leading global finance and accounting functions, investor relations, and business development, and she previously worked at Inogen, a medical technology company.
Dr. David Badawi, M.D., Founder & Chief Technology Officer
Dr. David Badawi is a co-founder and the Chief Technology Officer of Sight Sciences, Inc.
Jeremy Hayden, General Counsel & Chief Compliance Officer
Jeremy Hayden serves as the General Counsel & Chief Compliance Officer for Sight Sciences, Inc. He brings over 20 years of experience providing legal counsel to life science businesses, including serving as General Counsel and Chief Compliance Officer for Endologix, Inc., and General Counsel at Cytori Therapeutics, Inc. He was also a senior legal team member of Volcano prior to its acquisition by Royal Philips.
AI Analysis | Feedback
The key risks to Sight Sciences (SGHT) include:
- Persistent Cash Burn and Unprofitability: Sight Sciences faces ongoing financial challenges with a persistent cash burn and has been noted as currently unprofitable, with forecasts suggesting it may not achieve profitability within the next three years. The company has posted significant net losses, indicating struggles in achieving and maintaining a positive earnings profile despite efforts to manage costs.
- Delayed or Restrictive Insurance Coverage and Reimbursement: The company has encountered significant challenges with insurance coverage and reimbursement for its products, particularly the TearCare System. This issue limits the uptake of its technologies and has flattened revenue growth, making market access and reimbursement expansion critical for future success.
- Increasing Competition in the Minimally Invasive Glaucoma Surgery (MIGS) Market: Sight Sciences operates in a competitive landscape, specifically within the MIGS market with its OMNI Surgical System. The company faces increasing competition from other medical device companies, which can impact its market share and pricing power.
AI Analysis | Feedback
null
AI Analysis | Feedback
Sight Sciences (NASDAQ: SGHT) addresses significant markets with its primary products.
For its OMNI Surgical System, used to reduce intraocular pressure in adult glaucoma patients, the company targets an addressable market in the United States of approximately $6 billion. This U.S. market opportunity is further segmented into roughly $1.0 billion within the combination cataract procedure market and $5.0 billion in the standalone procedure market.
The TearCare System, which treats dry eye disease (DED), has an estimated addressable market opportunity in the United States of about $3 billion. The broader U.S. market for dry eye treatments was valued at $2.4 billion in 2025.
AI Analysis | Feedback
Sight Sciences (NASDAQ: SGHT) is expected to drive future revenue growth over the next 2-3 years through several key strategies centered around its core product portfolio and market expansion efforts.
- Continued Adoption and Enhancement of the OMNI Surgical System for Interventional Glaucoma: The OMNI Surgical System, a therapeutic device for reducing intraocular pressure in adult glaucoma patients, is projected to sustain growth, particularly through increasing its market share within the minimally invasive glaucoma surgery (MIGS) sector. This growth is further bolstered by targeted investments in standalone market education and commercialization. The recent launch of the OMNI Edge Surgical System in April 2025, featuring higher viscoelastic capacity and TruSync™ technology, is anticipated to enhance the product's appeal and drive increased adoption. Additionally, real-world data demonstrating OMNI's long-term effectiveness in reducing intraocular pressure (IOP) and medication use supports its continued utilization. Expanded coverage, such as UnitedHealthcare's inclusion of OMNI for glaucoma procedures starting October 2025, is also expected to broaden market reach.
- Rebound and Scaling of the TearCare System for Interventional Dry Eye: Sight Sciences anticipates a significant rebound in revenue from its Interventional Dry Eye segment, with projections of $5 million to $7 million in 2026, a substantial increase from $1.6 million in 2025. This expected growth is largely attributed to recent reimbursement gains, including the establishment of pricing for CPT code 0563T by Novitas and First Coast Service Options. The company plans to dedicate expanded market access and commercial resources to scale the reimbursed dry eye market. Clinical evidence also supports TearCare's efficacy in improving meibomian gland function and ocular surface health, and it has demonstrated cost savings and greater health utility compared to other treatments, which could encourage further adoption.
- Expansion of Market Access and Commercial Resources: To support the growth of both its glaucoma and dry eye segments, Sight Sciences plans to modestly increase adjusted operating expenses in 2026. These strategic investments are aimed at funding expanded market access and commercial resources, particularly to scale the reimbursed dry eye market and pursue opportunities in the pseudophakic standalone glaucoma market. Efforts include increasing the number of ordering accounts and enhancing utilization within existing customer bases across both interventional glaucoma and interventional dry eye.
AI Analysis | Feedback
Share Issuance
- Sight Sciences' issuance of common stock peaked in December 2021 at $257 million.
- The median issuance of common stock from fiscal years ending December 2020 to 2024 was $1.248 million.
- In Q4 2025, Sight Sciences had 53 million shares outstanding, which was an increase of 1.2% from the prior quarter.
Capital Expenditures
- Sight Sciences invested -$156,000 in capital expenditures in Q4 2025.
- Over the last 12 months, capital expenditures for Sight Sciences were -$224,000.
- The company anticipates adjusted operating expenses for full year 2026 to range from $93 million to $96 million, an increase of 6% to 9% compared to 2025, driven by targeted investments in market access and commercial resources for its business segments.
Peer Outperformance in Life Sciences Tools & Services
SGHT has outperformed 50% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it are A and CRL. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that SGHT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
89%
of 127 industry peers · 101.7% return
3Y
72%
of 117 industry peers · 25.2% return
5Y
50%
of 108 industry peers · -73.1% return
Life Sciences Tools & Services peers with revenue growth within 4pp of SGHT's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| SGHT | Sight Sciences | 0.9% | -15.0x | 101.7% | 25.2% | -73.1% | — |
| A | Agilent Technologies | 2.0% | 29.4x | 20.3% | 25.8% | -12.7% | +60pp |
| CRL | Charles River Laboratories International | -1.4% | -56.9x | 72.9% | 34.7% | -37.1% | +36pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is SGHT's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 14.4% | 94.0% | 140.0% | CAH 398% · MCK 349% · COR 179% |
| Managed Health Care | 8 | 31.6% | 1.1% | 1.5% | OSCR 63% · HQY 47% · ELV 13% |
| Health Care Services | 20 | 16.6% | 45.6% | -4.3% | HIMS 241% · RDNT 141% · DGX 68% |
| Health Care Equipment | 51 | -4.3% | -7.9% | -20.5% | POCI 10500% · UFPT 322% · GKOS 195% |
| Health Care Facilities | 24 | 6.2% | -4.7% | -20.7% | THC 250% · NHC 239% · ENSG 110% |
| Health Care Supplies | 12 | 29.8% | -17.0% | -37.5% | LNTH 272% · HAE 55% · MMSI 24% |
| Pharmaceuticals | 63 | -0.7% | 2.5% | -37.6% | LQDA 2281% · INDV 1175% · ETON 1040% |
| Life Sciences Tools & Services ← | 109 | -2.0% | -32.5% | -73.1% | SNWV 1778% · MEDP 201% · AXGN 182% |
| Biotechnology | 363 | 10.1% | -28.0% | -77.0% | BRTX 99050% · DNTH 1513% · CELZ 1471% |
| Health Care Technology | 20 | -26.2% | -59.5% | -78.0% | SPOK 72% · HSTM -1% · VEEV -12% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sight Sciences Earnings Notes | 12/16/2025 | |
| Would You Still Hold Sight Sciences Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.23 |
| Mkt Cap | 1.4 |
| Rev LTM | 815 |
| Op Inc LTM | -2 |
| FCF LTM | -2 |
| FCF 3Y Avg | -8 |
| CFO LTM | 57 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.3% |
| Rev Chg 3Y Avg | 2.3% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 42.7% |
| Op Inc Chg 3Y Avg | 25.5% |
| Op Mgn LTM | -0.7% |
| Op Mgn 3Y Avg | -5.1% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 6.9% |
| CFO/Rev 3Y Avg | -2.6% |
| FCF/Rev LTM | -0.7% |
| FCF/Rev 3Y Avg | -5.0% |
Price Behavior
Price Behavior
| Market Price | $8.19 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 07/15/2021 | |
| Distance from 52W High | -9.5% | |
| 50 Days | 200 Days | |
| DMA Price | $6.30 | $5.81 |
| DMA Trend | up | up |
| Distance from DMA | 30.0% | 41.1% |
| 3M | 1YR | |
| Volatility | 72.7% | 84.3% |
| Downside Capture | -97.57 | 189.68 |
| Upside Capture | 211.37 | 234.17 |
| Correlation (SPY) | 10.8% | 27.8% |
SGHT Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.07 | 0.93 | 0.53 | 1.41 | 1.82 | 1.71 |
| Up Beta | 0.63 | -1.14 | -0.75 | 0.03 | 0.83 | 1.43 |
| Down Beta | 13.10 | 5.61 | 2.62 | 2.05 | 2.09 | 1.17 |
| Up Capture | 412% | 257% | 162% | 302% | 471% | 2125% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 15 | 26 | 36 | 66 | 118 | 357 |
| Down Capture | -742% | -163% | -148% | 138% | 146% | 112% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 6 | 14 | 24 | 57 | 124 | 368 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | 102.3% | 84.2% | 1.18 | - |
| Sector ETF (XLV) | 26.7% | 16.0% | 1.29 | 25.3% |
| Equity (SPY) | 19.2% | 12.8% | 1.10 | 27.8% |
| Gold (GLD) | 24.8% | 29.2% | 0.76 | 5.4% |
| Commodities (DBC) | 44.0% | 20.4% | 1.67 | -14.0% |
| Real Estate (VNQ) | 8.5% | 13.7% | 0.35 | 23.5% |
| Bitcoin (BTCUSD) | -27.6% | 43.5% | -0.62 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | -23.7% | 91.0% | 0.16 | - |
| Sector ETF (XLV) | 6.4% | 15.1% | 0.24 | 24.8% |
| Equity (SPY) | 12.7% | 17.2% | 0.56 | 32.5% |
| Gold (GLD) | 18.7% | 18.7% | 0.81 | 6.1% |
| Commodities (DBC) | 11.0% | 19.5% | 0.44 | 2.0% |
| Real Estate (VNQ) | 2.0% | 18.9% | -0.00 | 25.2% |
| Bitcoin (BTCUSD) | 10.5% | 52.6% | 0.38 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | -11.6% | 90.5% | 0.18 | - |
| Sector ETF (XLV) | 10.5% | 16.7% | 0.51 | 25.1% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 32.6% |
| Gold (GLD) | 12.0% | 16.3% | 0.60 | 5.9% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 2.4% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 25.2% |
| Bitcoin (BTCUSD) | 63.2% | 66.1% | 1.03 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 27.7% | 49.2% | |
| 5/6/2026 | 23.0% | 14.0% | 3.5% |
| 3/4/2026 | -26.8% | -31.6% | -34.9% |
| 1/13/2026 | -7.8% | -15.8% | -25.4% |
| 11/6/2025 | 16.4% | 41.0% | 66.8% |
| 8/7/2025 | 19.4% | 19.7% | 3.9% |
| 5/8/2025 | 1.7% | 12.9% | 34.0% |
| 3/5/2025 | 2.9% | 11.2% | -7.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 8 | 9 |
| # Negative | 12 | 16 | 14 |
| Median Positive | 8.3% | 21.1% | 26.2% |
| Median Negative | -7.1% | -8.1% | -21.0% |
| Max Positive | 34.9% | 49.2% | 66.8% |
| Max Negative | -26.8% | -31.6% | -44.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 27.7% | 49.2% | |
| 5/6/2026 | 23.0% | 14.0% | 3.5% |
| 3/4/2026 | -26.8% | -31.6% | -34.9% |
| 1/13/2026 | -7.8% | -15.8% | -25.4% |
| 11/6/2025 | 16.4% | 41.0% | 66.8% |
| 8/7/2025 | 19.4% | 19.7% | 3.9% |
| 5/8/2025 | 1.7% | 12.9% | 34.0% |
| 3/5/2025 | 2.9% | 11.2% | -7.9% |
| 1/14/2025 | -2.8% | -10.8% | -21.0% |
| 11/7/2024 | -9.6% | -17.5% | -14.7% |
| 8/1/2024 | -15.0% | -21.4% | -8.8% |
| 3/7/2024 | 6.1% | -4.1% | 17.4% |
| 11/7/2023 | -1.9% | -1.9% | 26.2% |
| 8/3/2023 | 7.6% | -2.5% | -18.7% |
| 5/4/2023 | -6.3% | -6.5% | -29.9% |
| 3/13/2023 | 3.3% | -4.0% | -7.2% |
| 1/9/2023 | -9.4% | -6.6% | -11.0% |
| 11/10/2022 | 34.9% | 22.5% | 51.9% |
| 8/11/2022 | -1.0% | -16.9% | -24.8% |
| 5/10/2022 | 9.1% | 28.9% | 56.1% |
| 3/24/2022 | -8.8% | -21.6% | -44.1% |
| 1/10/2022 | 0.6% | -0.1% | 4.4% |
| 11/10/2021 | -3.0% | -9.5% | -21.0% |
| 8/12/2021 | -6.4% | -1.7% | -21.5% |
| SUMMARY STATS | |||
| # Positive | 12 | 8 | 9 |
| # Negative | 12 | 16 | 14 |
| Median Positive | 8.3% | 21.1% | 26.2% |
| Median Negative | -7.1% | -8.1% | -21.0% |
| Max Positive | 34.9% | 49.2% | 66.8% |
| Max Negative | -26.8% | -31.6% | -44.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/24/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 07/15/2021 | 424B4 |
Recent Forward Guidance
Updated 8/6/2026Latest: Q2 2026 Earnings Reported 8/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 88.00 Mil | 90.00 Mil | 92.00 Mil | 4.7% | Raised | Guidance: 86.00 Mil for 2026 | |
| 2026 Revenue Growth | Reported | 14.0% | 16.5% | 19.0% | ||||
| 2026 Interventional Glaucoma Revenue | Reported | 79.00 Mil | 80.00 Mil | 81.00 Mil | 1.3% | Raised | Guidance: 79.00 Mil for 2026 | |
| 2026 Interventional Glaucoma Revenue Growth | Reported | 4.0% | 5.5% | 7.0% | ||||
| 2026 Interventional Dry Eye Revenue | Reported | 9.00 Mil | 10.00 Mil | 11.00 Mil | 42.9% | Raised | Guidance: 7.00 Mil for 2026 | |
| 2026 Adjusted Operating Expenses | Reported | 92.00 Mil | 93.00 Mil | 94.00 Mil | -1.6% | Lowered | Guidance: 94.50 Mil for 2026 | |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 7062026 | 5.51 | 12,733 | 70,133 | 1,966,560 | Form |
| 2 | Badawi, David | Chief Technology Officer | Direct | Sell | 7062026 | 5.51 | 7,418 | 40,858 | 10,921,659 | Form |
| 3 | Rodberg, James | Chief Financial Officer | Direct | Sell | 7062026 | 5.36 | 6,902 | 36,995 | 1,200,838 | Form |
| 4 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 7062026 | 5.36 | 24,184 | 129,626 | 3,562,840 | Form |
| 5 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 7062026 | 5.42 | 2,829 | 15,333 | 1,436,181 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 7062026 | 5.51 | 12,733 | 70,133 | 1,966,560 | Form |
| 2 | Badawi, David | Chief Technology Officer | Direct | Sell | 7062026 | 5.51 | 7,418 | 40,858 | 10,921,659 | Form |
| 3 | Rodberg, James | Chief Financial Officer | Direct | Sell | 7062026 | 5.36 | 6,902 | 36,995 | 1,200,838 | Form |
| 4 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 7062026 | 5.36 | 24,184 | 129,626 | 3,562,840 | Form |
| 5 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 7062026 | 5.42 | 2,829 | 15,333 | 1,436,181 | Form |
| 6 | Badawi, Paul | President and CEO | Direct | Sell | 7062026 | 5.42 | 28,684 | 155,467 | 33,183,798 | Form |
| 7 | Encrantz, Staffan | Direct | Buy | 6112026 | 4.88 | 14,100 | 68,794 | 6,997,867 | Form | |
| 8 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 5192026 | 5.12 | 12,728 | 65,167 | 3,527,132 | Form |
| 9 | Rodberg, James | Chief Financial Officer | Direct | Sell | 4092026 | 3.55 | 7,231 | 25,670 | 819,833 | Form |
| 10 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 4092026 | 3.55 | 13,761 | 48,852 | 1,312,684 | Form |
| 11 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 4032026 | 3.48 | 25,874 | 90,042 | 2,441,641 | Form |
| 12 | Badawi, David | Chief Technology Officer | Direct | Sell | 4032026 | 3.48 | 8,168 | 28,425 | 6,926,209 | Form |
| 13 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 4032026 | 3.70 | 2,869 | 10,615 | 990,886 | Form |
| 14 | Badawi, Paul | President and CEO | Direct | Sell | 4032026 | 3.70 | 29,244 | 108,203 | 22,759,277 | Form |
| 15 | Badawi, David | Chief Technology Officer | Direct | Sell | 1212026 | 6.62 | 4,836 | 32,014 | 12,659,247 | Form |
| 16 | Rodberg, James | Chief Financial Officer | Direct | Sell | 1212026 | 6.62 | 2,616 | 17,318 | 1,001,143 | Form |
| 17 | Badawi, Paul | President and CEO | Direct | Sell | 1212026 | 6.62 | 22,362 | 148,036 | 39,891,061 | Form |
| 18 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 1212026 | 6.62 | 6,308 | 41,759 | 1,771,585 | Form |
| 19 | Badawi, Paul | President and CEO | Direct | Sell | 1062026 | 7.48 | 11,870 | 88,788 | 44,321,064 | Form |
| 20 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 1062026 | 7.48 | 1,785 | 13,352 | 1,835,742 | Form |
| 21 | Badawi, David | Chief Technology Officer | Direct | Sell | 1062026 | 7.48 | 3,695 | 27,639 | 14,339,975 | Form |
| 22 | Rodberg, James | Chief Financial Officer | Direct | Sell | 1062026 | 7.48 | 594 | 4,443 | 1,150,768 | Form |
| 23 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 1062026 | 7.48 | 9,647 | 72,160 | 4,487,873 | Form |
| 24 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 1062026 | 7.48 | 619 | 4,630 | 1,273,186 | Form |
| 25 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 1062026 | 7.82 | 9,385 | 73,391 | 1,933,143 | Form |
| 26 | Badawi, David | Chief Technology Officer | Direct | Sell | 1062026 | 7.82 | 3,051 | 23,859 | 15,020,687 | Form |
| 27 | Rodberg, James | Chief Financial Officer | Direct | Sell | 1062026 | 7.82 | 4,405 | 34,447 | 1,207,721 | Form |
| 28 | Bauerlein, Alison | Chief Operating Officer | Direct | Sell | 1062026 | 7.82 | 10,896 | 85,207 | 4,767,307 | Form |
| 29 | Badawi, Paul | President and CEO | Direct | Sell | 1062026 | 7.43 | 25,356 | 188,395 | 44,112,995 | Form |
| 30 | Badawi, David | Chief Technology Officer | Direct | Sell | 1062026 | 7.43 | 2,914 | 21,651 | 14,294,243 | Form |
| 31 | Encrantz, Staffan | Direct | Buy | 12182025 | 8.31 | 13,958 | 115,963 | 11,564,088 | Form | |
| 32 | Rodberg, James | Chief Financial Officer | Direct | Sell | 12032025 | 8.25 | 2,518 | 20,774 | 1,310,471 | Form |
| 33 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 11262025 | 8.08 | 44,850 | 362,388 | 2,073,247 | Form |
| 34 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 11182025 | 7.06 | 14,418 | 101,791 | 1,206,067 | Form |
| 35 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 11142025 | 8.01 | 3,150 | 25,232 | 2,055,286 | Form |
| 36 | Taylor, Brenton | EVP, Operations & R&D | Direct | Sell | 10082025 | 3.37 | 591 | 1,992 | 624,289 | Form |
| 37 | Badawi, David | Chief Technology Officer | Direct | Sell | 10032025 | 3.27 | 6,033 | 19,728 | 6,098,524 | Form |
| 38 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 10032025 | 3.27 | 9,731 | 31,820 | 839,049 | Form |
| 39 | Bauerlein, Alison | Chief Financial Officer | Direct | Sell | 10032025 | 3.30 | 19,948 | 65,828 | 1,971,816 | Form |
| 40 | Badawi, Paul | President and CEO | Direct | Sell | 10032025 | 3.34 | 24,441 | 81,633 | 19,914,757 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/1/2026